{"date":"2025-10-22","count":19,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6535-2025-10-22-2019-1ks33eg","company_id":"6535","company":"順藥","market":"上櫃","industry":"生技醫療","date":"2025-10-22","time":"20:19:29","subject":"公告本公司2024年11月已完成之LT3001二期臨床試驗成果於 世界中風大會 （WSC 2025）口頭發表","clause":"第53款","fact_date":"2025-10-22","cite_as":"公開資訊觀測站重大訊息：順藥（6535），2025-10-22 20:19，「公告本公司2024年11月已完成之LT3001二期臨床試驗成果於 世界中風大會 （WSC 2025）口頭發表」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4116-2025-10-22-1745-1i2a0qt","company_id":"4116","company":"明基醫","market":"上櫃","industry":"生技醫療","date":"2025-10-22","time":"17:45:01","subject":"民國114年第三季財務報告董事會預計召開日期為民國114年10月30日","clause":"第31款","fact_date":"2025-10-22","cite_as":"公開資訊觀測站重大訊息：明基醫（4116），2025-10-22 17:45，「民國114年第三季財務報告董事會預計召開日期為民國114年10月30日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7803-2025-10-22-1735-17vkp6y","company_id":"7803","company":"雲象科技-創","market":"上市","industry":"生技醫療","date":"2025-10-22","time":"17:35:29","subject":"公告本公司董事會委任薪資報酬委員會委員","clause":"第6款","fact_date":"2025-10-22","cite_as":"公開資訊觀測站重大訊息：雲象科技-創（7803），2025-10-22 17:35，「公告本公司董事會委任薪資報酬委員會委員」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7850-2025-10-22-1733-10qn6yl","company_id":"7850","company":"寶泰生醫","market":"興櫃","industry":"生技醫療","date":"2025-10-22","time":"17:33:30","subject":"公告本公司更換股務代理機構案經集保公司准予備查","clause":"第44款","fact_date":"2025-10-22","cite_as":"公開資訊觀測站重大訊息：寶泰生醫（7850），2025-10-22 17:33，「公告本公司更換股務代理機構案經集保公司准予備查」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6891-2025-10-22-1700-1dcfws6","company_id":"6891","company":"樂迦再生","market":"興櫃","industry":"生技醫療","date":"2025-10-22","time":"17:00:05","subject":"本公司配合檢調單位進行調查","clause":"第16款","fact_date":"2025-10-22","cite_as":"公開資訊觀測站重大訊息：樂迦再生（6891），2025-10-22 17:00，「本公司配合檢調單位進行調查」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4126-2025-10-22-1652-kjds6o","company_id":"4126","company":"太醫","market":"上櫃","industry":"生技醫療","date":"2025-10-22","time":"16:52:20","subject":"本公司受邀參加永豐金證券與櫃買中心合辦之線上「台灣投資論壇」","clause":"第12款","fact_date":"2025-10-23","cite_as":"公開資訊觀測站重大訊息：太醫（4126），2025-10-22 16:52，「本公司受邀參加永豐金證券與櫃買中心合辦之線上「台灣投資論壇」」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7754-2025-10-22-1652-uj36tl","company_id":"7754","company":"安基生技","market":"興櫃","industry":"生技醫療","date":"2025-10-22","time":"16:52:01","subject":"公告AJ201獲美國食品藥物管理局(FDA)通知授予治療脊髓和延髓肌肉萎縮症（簡稱SBMA或甘迺迪氏症）新藥「快速審查認定」(Fast Track Designation)","clause":"第44款","fact_date":"2025-10-22","cite_as":"公開資訊觀測站重大訊息：安基生技（7754），2025-10-22 16:52，「公告AJ201獲美國食品藥物管理局(FDA)通知授予治療脊髓和延髓肌肉萎縮症（簡稱SBMA或甘迺迪氏症）新藥「快速審查認」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6730-2025-10-22-1553-5sggiz","company_id":"6730","company":"常廣","market":"上櫃","industry":"生技醫療","date":"2025-10-22","time":"15:53:32","subject":"本公司受邀參加第一金證券舉辦之法人說明會","clause":"第30款","fact_date":"2025-10-23","cite_as":"公開資訊觀測站重大訊息：常廣（6730），2025-10-22 15:53，「本公司受邀參加第一金證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7595-2025-10-22-1542-afm8ji","company_id":"7595","company":"世基生醫","market":"興櫃","industry":"生技醫療","date":"2025-10-22","time":"15:42:46","subject":"公告本公司經主管機關核准撤銷114年第一次現金增資發行新股案","clause":"第44款","fact_date":"2025-10-22","cite_as":"公開資訊觀測站重大訊息：世基生醫（7595），2025-10-22 15:42，「公告本公司經主管機關核准撤銷114年第一次現金增資發行新股案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4195-2025-10-22-1541-1ialwbs","company_id":"4195","company":"基米-創","market":"上市","industry":"生技醫療","date":"2025-10-22","time":"15:41:23","subject":"更新本公司113年度關係企業三書表部份內容","clause":"第44款","fact_date":"2025-10-22","cite_as":"公開資訊觀測站重大訊息：基米-創（4195），2025-10-22 15:41，「更新本公司113年度關係企業三書表部份內容」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6827-2025-10-22-1531-dqh4gv","company_id":"6827","company":"巨生醫","market":"興櫃","industry":"生技醫療","date":"2025-10-22","time":"15:31:08","subject":"公告本公司114年度現金增資收足股款暨增資基準日","clause":"第44款","fact_date":"2025-10-22","cite_as":"公開資訊觀測站重大訊息：巨生醫（6827），2025-10-22 15:31，「公告本公司114年度現金增資收足股款暨增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7799-2025-10-22-1527-vbaae5","company_id":"7799","company":"禾榮科","market":"上市","industry":"生技醫療","date":"2025-10-22","time":"15:27:31","subject":"本公司與日本筑波大學簽署臨床研究與技術發展合作協議","clause":"第10款","fact_date":"2025-10-22","cite_as":"公開資訊觀測站重大訊息：禾榮科（7799），2025-10-22 15:27，「本公司與日本筑波大學簽署臨床研究與技術發展合作協議」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4162-2025-10-22-1420-109jtcw","company_id":"4162","company":"智擎","market":"上櫃","industry":"生技醫療","date":"2025-10-22","time":"14:20:30","subject":"本公司受邀參加元大證券舉辦之線上法說會","clause":"第12款","fact_date":"2025-11-03","cite_as":"公開資訊觀測站重大訊息：智擎（4162），2025-10-22 14:20，「本公司受邀參加元大證券舉辦之線上法說會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4162-2025-10-22-1419-1vm2c7c","company_id":"4162","company":"智擎","market":"上櫃","industry":"生技醫療","date":"2025-10-22","time":"14:19:34","subject":"公告114年第三季財務報告董事會召開日期","clause":"第31款","fact_date":"2025-10-22","cite_as":"公開資訊觀測站重大訊息：智擎（4162），2025-10-22 14:19，「公告114年第三季財務報告董事會召開日期」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6657-2025-10-22-1405-1kn4001","company_id":"6657","company":"華安","market":"上市","industry":"生技醫療","date":"2025-10-22","time":"14:05:28","subject":"本公司接獲CRO機構通知，本公司研發中新藥ENERGI-F703EB遺傳性表皮分解性水皰症乳膏，向美國食品藥物管理局(FDA)申請執行人體二期臨床試驗(IND)。","clause":"第10款","fact_date":"2025-10-22","cite_as":"公開資訊觀測站重大訊息：華安（6657），2025-10-22 14:05，「本公司接獲CRO機構通知，本公司研發中新藥ENERGI-F703EB遺傳性表皮分解性水皰症乳膏，向美國食品藥物管理局(F」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7827-2025-10-22-1359-1fqkmsr","company_id":"7827","company":"漢康-KY創","market":"上市","industry":"生技醫療","date":"2025-10-22","time":"13:59:58","subject":"澄清媒體報導","clause":"第26款","fact_date":"2025-10-22","cite_as":"公開資訊觀測站重大訊息：漢康-KY創（7827），2025-10-22 13:59，「澄清媒體報導」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6709-2025-10-22-1003-1kbupvl","company_id":"6709","company":"昱厚生技","market":"興櫃","industry":"生技醫療","date":"2025-10-22","time":"10:03:40","subject":"公告修正本公司113年度股東會年報部分內容","clause":"第44款","fact_date":"2025-10-22","cite_as":"公開資訊觀測站重大訊息：昱厚生技（6709），2025-10-22 10:03，「公告修正本公司113年度股東會年報部分內容」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4147-2025-10-22-0800-1ue3cwr","company_id":"4147","company":"中裕","market":"上櫃","industry":"生技醫療","date":"2025-10-22","time":"08:00:06","subject":"中裕新藥於ID Week 2025發表全球首創CD4+標靶抗體藥物複合體(ADC)用於HIV治療的前瞻性成果","clause":"第53款","fact_date":"2025-10-22","cite_as":"公開資訊觀測站重大訊息：中裕（4147），2025-10-22 08:00，「中裕新藥於ID Week 2025發表全球首創CD4+標靶抗體藥物複合體(ADC)用於HIV治療的前瞻性成果」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7784-2025-10-22-0034-1roellr","company_id":"7784","company":"安邦生技*","market":"興櫃","industry":"生技醫療","date":"2025-10-22","time":"00:34:17","subject":"公告本公司董事辭任","clause":"第9款","fact_date":"2025-10-21","cite_as":"公開資訊觀測站重大訊息：安邦生技*（7784），2025-10-22 00:34，「公告本公司董事辭任」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}